Premium
HLA class II genotype and factor VIII inhibitors in mild haemophilia A patients with an Arg 593 to Cys mutation
Author(s) -
Bril W. S.,
MacLean P. E.,
Kaijen P. H. P.,
Brink E. N.,
Lardy N. M.,
Fijnvandraat K.,
Peters M.,
Voorberg J.
Publication year - 2004
Publication title -
haemophilia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.213
H-Index - 92
eISSN - 1365-2516
pISSN - 1351-8216
DOI - 10.1111/j.1365-2516.2004.01011.x
Subject(s) - haemophilia a , human leukocyte antigen , medicine , haemophilia , genotype , mutation , antibody , titer , genotyping , allele , immunology , microbiology and biotechnology , gastroenterology , antigen , genetics , biology , pediatrics , gene
Summary. We evaluated inhibitor formation in a group of patients with mild haemophilia A caused by an Arg 593 to Cys mutation. A remarkably high cumulative inhibitor incidence of 14% over 22 years was observed. Three of 49 patients developed transient, low‐titre inhibitors, which remained below 2.0 BU mL −1 . Four patients with an Arg 593 to Cys mutation developed high‐titre inhibitors (>5.0 BU mL −1 ). Three of these patients have been described previously. In this study, we characterized inhibitory antibodies in a fourth patient with high‐titre inhibitors. Epitope mapping studies revealed that antibodies were predominantly directed to the A2 domain of factor VIII. We addressed the role of human leucocyte antigen (HLA) class II alleles in inhibitor development in patients with an Arg 593 to Cys mutation by HLA genotyping. In the group of inhibitor patients raised frequencies of HLA‐DRB1*01 and HLA‐DQB1*05 were observed that did not reached statistical significance. Our data suggest that inhibitor development in mild haemophilia A patients with an Arg 593 to Cys mutation is not linked to HLA class II profile.